Scarica l'app Stockscreener
1.52
5.00%
-0.08
Dopo l'orario di chiusura:
1.50
-0.02
-1.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.60
Aprire:
$1.55
Volume 24 ore:
1.35M
Relative Volume:
0.71
Capitalizzazione di mercato:
$285.60M
Reddito:
-
Utile/perdita netta:
$-222.39M
Rapporto P/E:
-1.1456
EPS:
-1.3268
Flusso di cassa netto:
$-193.40M
1 W Prestazione:
-6.17%
1M Prestazione:
-5.59%
6M Prestazione:
-57.06%
1 anno Prestazione:
-6.75%
Intervallo 1D:
$1.46
$1.585
Intervallo di 1 settimana:
$1.46
$1.785
Portata 52W:
$0.8302
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.52 | 300.63M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch - Stock Titan
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Neumora Therapeutics Q2 Results: Net loss narrows to $43.1 million - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Results and Advances Pipeline Amid Leadership Changes - Quiver Quantitative
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Neumora Names Joshua Pinto CEO as 2026 Clinical Milestones Near - Stock Titan
Neumora Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
NMRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutic - The National Law Review
Neumora Therapeutics (NMRA) Gains 2.48% as Biotech Stock Holds Above $1.57 SupportCatalyst Driven Stocks - dars.gov.et
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE) - The Globe and Mail
Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA - TradingView
Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares SlipMargin Compression Risk - dars.gov.et
Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday - MarketBeat
H.C. Wainwright reiterates Neumora stock rating on positive toxicology data By Investing.com - Investing.com Nigeria
Neumora reports favorable toxicology results for obesity drug By Investing.com - Investing.com Nigeria
Neumora Therapeutics | 8-K: Current report - Moomoo
Neumora Therapeutics Shares Rise on Positive Obesity Drug Results - Moomoo
NMRA|Neumora Therapeutics Inc|Price:1.456|Chg%:-0.034 - TradingKey
New toxicology data support advancement of Neumora Therapeutics’ NMRA-215 - BioWorld News
Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study - marketscreener.com
Neumora reports favorable toxicology results for obesity drug - Investing.com
Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026 - Quiver Quantitative
Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan
Neumora Therapeutics Inc (NMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NMRA|Neumora Therapeutics Inc|Price:1.490|Chg%:-0.070 - TradingKey
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Cash Flow - TradingKey
TradingKey - TradingKey
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA - MarketBeat
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7. 2025NMRA - TMX Newsfile
Neumora Therapeutics (NMRA) AGM 2026 Summary - Quartr
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NMRA) Slides to $1.6 as Biotech Sector Headwinds PersistReversal Setup Alerts - dars.gov.et
Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - MarketBeat
Neumora Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neumora Therapeutics Inc Azioni (NMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):